GFAP and Alzheimer disease: Notably, some inflammatory mediators have been used as AD markers, such as TNF-α, IL-1β, Iba-1, GFAP, NF-κB, TLR2, and MHCII, and the use of anti-inflammatory drugs has become a potential therapeutic approach for AD [35,36,37].